Low-dose Pembrolizumab Plus Chemotherapy for the First-Line Treatment of Persistent, Recurrent, or Metastatic Cervical Cancer.
Clinical trial NCT06670911 · RECRUITING
Trial details
- NCT number
- NCT06670911
- Sponsor
- Instituto Nacional de Cancer, Brazil
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-20
- Primary completion
- 2026-04-01
- Enrollment
- 44
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.